Market News AIOpen the app

NKTR stock news · Nektar Therapeutics

Stories about Nektar Therapeutics (NKTR) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for NKTR

Follow Nektar Therapeutics (NKTR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NKTR
Free on the App Store and Google Play, or on the web.
  1. Nov 12, 2026, 4:30 PM ET · Market

    Nektar Therapeutics shared its third-quarter results, showing a loss and updates on its clinical trials.

    Neutral

    Nektar reported $9.4 million in quarterly sales, down from $11.8 million, and $952.9 million in cash and investments. Phase 3 progress helps, but rising costs and losses leave its outlook unchanged.

  2. Oct 1, 2026, 1:15 PM ET · Market

    On Thursday, 12 health care stocks saw big price changes, with Nexalin Technology jumping up 77.8%.

    Neutral

    Nektar Therapeutics shares fell 21.3% during Thursday's session, but the article gives no company news explaining the drop, so its business outlook is unchanged.

  3. Oct 1, 2026, 8:02 AM ET · Market

    Nektar Therapeutics shares new information about its alopecia areata study.

    Neutral

    Nektar said it released new data from an alopecia areata trial. The filing text does not show the findings, so it does not change the view of the company.

  4. Sep 8, 2026, 4:16 PM ET · Market

    Nektar Therapeutics says it has started a quiet period for its clinical study on rezpegaldesleukin.

    Neutral

    Nektar Therapeutics filed a Form 8-K indicating the start of a quiet period on September 8, 2026, in relation to its ongoing clinical study for rezpegaldesleukin.